About US
Contact us
-
Newron submits new drug application to FDA for Parkinson's disease treatmentNewron Pharmaceuticals has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for safinamide, which is being developed as an add-on therapy to dopamine agonists or to2014/6/3
-
Eisai's antiemetic agent Aloxi gets FDA approval to treat childrenJapan-based Eisai has received approval from the US Food and Drug Administration (FDA) for antiemetic agent Aloxi (palonosetron HCI) as an additional indication for preventing acute nausea and vomitin2014/6/3
-
Bristol-Myers Squibb collaborates with CytomX on immuno-oncology targetsBristol-Myers Squibb has signed a worldwide research collaboration and licence agreement with CytomX Therapeutics to discover, develop and commercialise new therapies using CytomX's Probody platform a2014/5/30
-
Celerion and KDDF sign agreement to advance drug discovery in South KoreaUS-based Celerion and the Korean Drug Development Fund (KDDF) have signed a collaboration agreement aimed at strengthening early phase clinical research in South Korea. A memorandum of understanding2014/5/30
-
Advaxis receives orphan drug designation for osteosarcoma immunotherapyAdvaxis has received orphan drug designation (ODD) from the US Food and Drug Administration's (FDA) Office of Orphan Products Development for its ADXS-cHER2, indicated for treatment of osteosarcoma.2014/5/29
-
EMA adopts positive opinion on Octapharma’s haemophilia A drug NuwiqThe European Medicines Agency (EMA) has given a positive opinion towards Octapharma's human cell line recombinant human FVIII, Nuwiq, recommending the granting of marketing authorisation for treatment2014/5/29
-
Teva and Active Biotech to Continue with the Development of Nerventra (Laquinimod) for MS Following Confirmation of CHMP OpinionTeva Pharmaceutical Industries Ltdand Active Biotechhave announced that the Committee for Medicinal Products for Human Use (CHMP) confirmed its 23 January 2014 opinion to recommend against approval fo2014/5/28
-
Health Canada approves Janssen’s type 2 diabetes mellitus medicationJohnson & Johnson subsidiary Janssen has announced Health Canada's approval for Invokana (canagliflozin), indicated as an adjunct to diet and exercise to improve glycemic control in adult patients2014/5/28
-
Alcon Receives Positive CHMP Opinion for Simbrinza, a New Fixed-Dose Combination Medicine to Treat Patients with GlaucomaAlcon,a global leader in eye care and division of Novartis, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive op2014/5/27
-
FDA Approves First-Line Use of Vectibix (Panitumum​ab) Plus FOLFOX for Patients with Wild-Type KRAS Metastatic Colorectal CancerAmgenhas announced thatFDA has approved Vectibix (panitumumab) for use in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as first-line treatment in patients with wild-type KRAS (e2014/5/27